PharmaEssentia · 23 hours ago
Associate Director, Commercial Scientific Training
PharmaEssentia USA is a rapidly growing biopharmaceutical innovator focused on delivering effective new biologics for challenging diseases in hematology and oncology. The Associate Director, Commercial Scientific Training will lead the development and execution of training programs to enhance the capabilities of field teams engaging with Health Care Providers.
BiotechnologyHealthcarePharmaceuticalHealth Care
Responsibilities
Develop and implement a comprehensive vision, strategy, and tactical plan to enhance the scientific acumen and engagement capabilities of Field Commercial teams
Lead the creation and delivery of scientific training programs including self-paced modules, live sessions, and virtual workshops, knowledge retention tools, to ensure consistent and effective knowledge dissemination
Work closely with internal departments such as Medical, Analytics & Informatics, Managed Markets, and other stakeholders to develop resources and tools for all field teams
Oversee the development of training materials and tools that support field-based interactions, ensuring alignment with overall company strategies and in full compliance with regulatory and operational standards
Ensures timely and efficient development and delivery of scientific learning content/training related to disease state, product, and treatment landscape
Advise on enhancements to digital tools and systems that support field efficiency and external engagement, aiming to streamline processes and reduce administrative burdens
Monitor and assess the effectiveness of training programs and materials, validate and update as appropriate existing materials, generate routine reports implement improvements based on feedback and evolving team needs
Working knowledge of relevant Medical Affairs regulations and quality standards, with experience in supporting quality, compliance, and legal/ethics training
Qualification
Required
5+ years successful sales and/or commercial training experience in hematology/oncology
Up to 30% travel to allow for field engagement, attendance at regional and national trainings, etc
Entrepreneurial spirit and ability to work in a fast-paced and ever-evolving environment, as well as a proven track record of working effectively in diverse teams involving multi-functional disciplines
Ability to work in a fast-paced and ever-evolving environment, as well as a proven track record of working effectively in diverse teams involving multi-functional disciplines
Disease State/Product training, presentation, and facilitation expertise
Excellent planning and organizational skills to demonstrate leadership and initiative
Strong scientific background, with the ability to critically review and analyze scientific literature in an objective manner and concisely summarize and communicate key information
Strong individual project management skills and works collaboratively with vendors to meet project and event timelines to deliver high-quality materials
Creative and strategic thinker possessing excellent written, oral, and presentation skills
Goal-oriented with a strong sense of urgency and the ability to address complex problems across projects
Preferred
Education: Scientific / Clinical / Medical educational background preferred
Advanced Scientific Degree (e.g., PA, NP, RN, OCN, PharmD) preferred
Professional experience: Clinical experience working with benign Hematology is and/or previous experience working in similar role highly preferred
A track record of proven success in areas of high-risk, high reward scenarios would also be beneficial
Experience creating interactive content of various media types with e-learning software experience
Benefits
Comprehensive medical coverage
Dental and vision coverage
Generous paid time-off
401(k) retirement plan with competitive company match
Medical & Dependent Care Flexible Spending Account
Up to $150 monthly cell phone reimbursement
Employee Assistance Program
Free parking
Company
PharmaEssentia
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis, and other diseases.
Funding
Current Stage
Public CompanyTotal Funding
$462.7M2024-01-25IPO
2023-04-17Post Ipo Equity· $462.7M
2022-08-15Post Ipo Equity
Leadership Team
Ko-Chung Lin
Founder and Chief Executive Officer
Recent News
2026-01-16
2026-01-15
Company data provided by crunchbase